In DLBCL cases with positive HCV NS3 and CD30 expressions, it is recommended to give antiviral therapy, either a combination of pegylated interferon-α (Peg-IFN-α) and ribavirin (RBV) or direct-acting antiviral (DAA) therapy. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.